Instil Bio upgraded by Truist with a new price target
$TIL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Truist upgraded Instil Bio from Hold to Buy and set a new price target of $52.00 from $11.00 previously
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/7/2025 | $11.00 → $52.00 | Hold → Buy | Jefferies |
| 1/7/2025 | $11.00 → $52.00 | Hold → Buy | Truist |
| 11/4/2024 | Mkt Perform | JMP Securities | |
| 4/12/2024 | $5.00 → $11.00 | Buy → Hold | Jefferies |
| 11/1/2022 | $16.00 → $6.00 | Buy → Hold | Truist |
| 11/1/2022 | Outperform → Market Perform | Cowen | |
| 8/13/2021 | $34.00 | Outperform | Robert W. Baird |
| 8/13/2021 | $34.00 | Outperform | Baird |
Jefferies upgraded Instil Bio from Hold to Buy and set a new price target of $52.00 from $11.00 previously
Truist upgraded Instil Bio from Hold to Buy and set a new price target of $52.00 from $11.00 previously
JMP Securities initiated coverage of Instil Bio with a rating of Mkt Perform
8-K - Instil Bio, Inc. (0001789769) (Filer)
8-K - Instil Bio, Inc. (0001789769) (Filer)
8-K - Instil Bio, Inc. (0001789769) (Filer)
4 - Instil Bio, Inc. (0001789769) (Issuer)
4 - Instil Bio, Inc. (0001789769) (Issuer)
4 - Instil Bio, Inc. (0001789769) (Issuer)
Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients Safety profile supports further clinical development, with no dose-limiting toxicities observed in patients with front-line NSCLC ImmuneOnco expects to present updated safety and efficacy data at a future medical conference DALLAS and SHANGHAI, July 31, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (NASDAQ:TIL, "Instil")) noted that ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK) ("ImmuneOnco"), today announced preliminary safety and efficacy data from the Phase 2 open-label, multicenter study of IMM2510/AXN-2510 (‘2510) in combination with ch
US phase 1 trial of ‘2510 is expected to be initiated before the end of 2025 Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of ‘2510 + chemo in 1L NSCLC in the second half of 2025 DALLAS, July 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the clearance of an Investigational New Drug (IND) application for AXN-2510 ("'2510") by the U.S. Food and Drug Administration. Instil expects to initiate a phase 1 trial of ‘2510 as monotherapy for patients with relapsed/refractory solid tumors before the end of 2025. The trial i
DALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the addition of John Maraganore, Ph.D., to the Board of Directors of Axion Bio, Inc., Instil's wholly-owned subsidiary dedicated to the development of AXN-2510 ("'2510"), a potentially best-in-class PD-L1xVEGF bispecific antibody for solid tumors prioritizing front-line non-small cell lung cancer (NSCLC). "John's appointment reflects our commitment to assembling world-class leadership to maximize the value of the ‘2510 program for patients and shareholders, and we have benefited greatly fr
SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)
SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)
SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)
DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel cancer therapies, today announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer. Dr. Freedman brings deep experience in oncology drug development and other therapeutic areas, and a track record of leading programs through all phases of development, regulatory approval and commercialization. Bronson Crouch, CEO of Instil, stated, "We are thrilled to welcome Dr. Freedman as Chief Medical Officer. Jamie's extensive experience and leadership in biopharmaceutical R&D will be a tremendous asset in adva
Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1'23 Reprioritization of resources with enrollment deferred in DELTA-2 trial of ITIL-168 First patient with non-small cell lung cancer dosed with ITIL-306, the first engineered TIL therapy using CoStAR Platform, with plans to share clinical data in 2023 Appointment of cell therapy pioneer Dr. Robert Hawkins as Head of Research and Development, and resignation of Chief Medical Officer, Dr. Zachary Roberts Company confirms cash runway into 2025 with anticipated sale-leaseback transaction of its Tarzana manufacturing facility DALLAS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("
DALLAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced the appointment of Tim Moore to the role of Chief Operating Officer. Tim Moore has more than three decades of leadership experience in biopharmaceutical manufacturing and operations, including at Genentech, Kite and most recently PACT Pharma. From 2016 to 2019, Mr. Moore was Executive Vice President, Technical Operations at Kite Pharma, where he was responsible for technical operations and successfully launched Yescarta®, one of the fi